Science

Ciro Franzese: An international multicenter study of stereotactic radiotherapy for renal cell carcinoma

Ciro Franzese/LinkedIn

Feb 8, 2025, 07:34

Ciro Franzese: An international multicenter study of stereotactic radiotherapy for renal cell carcinoma

Ciro Franzese, Associate Professor in Radiation Oncology at Humanitas University, shared on LinkedIn:

“Joining forces against kidney cancer!

Proud to have contributed to an international multicenter study of stereotactic radiotherapy for renal cell carcinoma.

SBRT is confirmed as a valid therapeutic option with:

96% local control at 5 years
Good preservation of renal function
acceptable toxicity profile, with only 1% of events grade ≥ 3

A step forward to offer inoperable patients an effective and non-invasive therapeutic option.”

Results of Stereotactic Body Radiation Therapy for Primary Renal Cell Carcinoma in a Large Multicenter Series

Authors: Ludwige Abancourt, et al.

Ciro Franzese: An international multicenter study of stereotactic radiotherapy for renal cell carcinoma

cancer Ciro Franzese fight against cancer Global awareness Global fight against cancer Large Multicenter Series non-invasive OncoDaily Oncology renal cell carcinoma Stereotactic Radiotherapy

Stanley Tucci and Throat Cancer: How He Went Against, How He Survived, and More

Senator John Fetterman Responds to Oncodaily on Pediatric Oncology Funding

Does Processed Meat Cause Cancer? Myths and Facts

Global Health Dialogues with Princess Dina Mired | Episode 1: Dr. Firas Al-Hawari

NEW PAPER ALERT: ESOPEC trial on Perioperative Chemotherapy or Preoperative Chemoradiotherapy in Esophageal Cancer